PeakShares LLC Invests $1.10 Million in Regeneron Pharmaceuticals, Inc. $REGN

PeakShares LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 1,428 shares of the biopharmaceutical company’s stock, valued at approximately $1,102,000. Regeneron Pharmaceuticals accounts for approximately 1.1% of PeakShares LLC’s portfolio, making the stock its 24th biggest holding.

Other institutional investors have also modified their holdings of the company. WPG Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. Board of the Pension Protection Fund acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Guggenheim increased their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Finally, Barclays decreased their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $792.65.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $609.94 on Friday. The company’s fifty day simple moving average is $676.81 and its 200-day simple moving average is $732.29. Regeneron Pharmaceuticals, Inc. has a 52 week low of $506.38 and a 52 week high of $821.11. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market cap of $64.48 billion, a P/E ratio of 14.86, a PEG ratio of 1.34 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s revenue was up 19.0% on a year-over-year basis. During the same period last year, the business earned $8.22 EPS. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.